Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: A critical examination of efficacy and safety

American Journal of Obstetrics and Gynecology

Volumn 214, Issue 1, 2016, Pages 45-56

  O'Brien, John M ^a   Lewis, David F ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

17 OHPC; adverse event; biomarker; cervical length; early preterm birth; history of preterm birth; metaanalysis; multiple gestation; pharmacodynamics; progestogens; safety; short cervix; twin gestation

Indexed keywords

17-ALPHA-HYDROXY-PROGESTERONE CAPROATE; GESTAGEN; PROGESTERONE; PROGESTERONE DERIVATIVE;

CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; FEMALE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; PREGNANCY; PREMATURE BIRTH;

ADMINISTRATION, INTRAVAGINAL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYPROGESTERONES; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS;

EID: 84955450671     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2015.10.934     Document Type: Review

References (100)

1. R. Romero, L. Yeo, J. Miranda, and et al. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix J Perinat Med 41 2013 27 44
2. D.F. Lewis, S.L. Baker, and R. Stauffer Short cervix and vaginal progesterone: a model on how to tackle the problem of idiopathic preterm labor J Reprod Med 58 2013 434 437
3. Society for Maternal Fetal Medicine publications committee, with assistance of Berghella V Progesterone and preterm birth prevention: translating clinical trials data into clinical practice Am J Obstet Gynecol 206 2012 376 386
4. ACOG Committee on Practice Bulletins - Obstetrics Prediction and prevention of preterm birth Obstet Gynecol 120 2012 964 973
5. J.D. Iams Prevention of preterm parturition N Engl J Med 370 2014 254 261
6. B.M. Mercer, R.L. Goldenberg, A.H. Moawad, and et al. The Preterm Prediction Study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome Am J Obstet Gynecol 181 1999 1216 1221
7. C.Y. Spong Prediction and prevention of recurrent spontaneous preterm birth Obstet Gynecol 110 2007 405 415
8. C.V. Ananth, D. Getahun, M.R. Peltier, H.M. Salihu, and A.M. Vintzileos Recurrence of spontaneous versus medically indicated preterm birth Am J Obstet Gynecol 195 2006 643 650
9. S. Mazaki-Tovi, R. Romero, J.P. Kusanovic, and et al. Recurrent preterm birth Semin Perinatol 31 2007 142 158
10. J.D. Iams, R.L. Goldenberg, P.J. Meis, and et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development N Engl J Med 334 1996 567 572
11. V. Berghella, A. Roman, C. Daskalakis, A. Ness, and J.K. Baxter Gestational age at cervical length measurement and the incidence of preterm birth Obstet Gynecol 110 2007 311 317
12. R.L. Goldenberg, J. Iams, M. Miodovnik, and et al. The preterm prediction study: risk factors in twin gestation: National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Am J Obstet Gynecol 175 1996 1047 1053
13. A.G. Cahill, A.O. Odibo, A.B. Caughey, and et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis Am J Obstet Gynecol 202 2010 548.e1 548.e8
14. E.F. Werner, C.S. Hans, C.M. Pettker, and et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis Ultrasound Obstet Gynecol 38 2011 32 37
15. Mills AA, Yonish B, Feng L, Schomberg DW, Heine RP, Murtha AP. Characterization of progesterone receptor isoform expression in fetal membranes. 2006;195:998-1003.
16. A.P. Murtha, L. Feng, B. Yonish, P.C. Leppert, and D.W. Schomberg Progesterone protects fetal chorion and maternal decidua cells from calcium-induced death Am J Obstet Gynecol 196 2007 257.e1 257.e5
17. R.A. Word, X.H. Li, M. Hnat, and K. Carrick Dynamics of cervical remodeling during pregnancy and parturition: mechanisms and current concepts Semin Reprod Med 25 2007 69 79
18. J.M. O'Brien Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens Ultrasound Obstet Gynecol 42 2013 247 253
19. S.N. Caritis, H.N. Simhan, Y. Zhao, and et al. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation Am J Obstet Gynecol 207 2012 396.e1 396.e8
20. C. Nold, M. Maubert, L. Anton, S. Yellon, and M.A. Elovitz Prevention of preterm birth by progestational agents: what are the molecular mechanisms? Am J Obstet Gynecol 208 2013 223.e1 223.e7
21. S. Aksel, R. Yoeman, J. Hazelton, and et al. Effects of 17-hydroxyprogesterone caproate (17-OHPC) administration in pregnant squirrel monkeys Am J Primatol 25 1991 175 183
22. C.D. Cuppett, Y. Zhao, S. Caritis, and et al. Effect of endogenous steroid hormones on 17-alpha-hydroxyprogesterone caproate metabolism Am J Obstet Gynecol 208 2013 86.e1 86.e6
23. B. Attardi, A. Zeleznik, H. Simhan, J.P. Chiao, D.R. Mattison, and S.N. Caritis Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins Am J Obstet Gynecol 197 2007 599.e1 599.e7
24. H. Xu, J.M. Gonzalez, E. Ofori, and M.A. Elovitz Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth? Am J Obstet Gynecol 198 2008 314.e1 314.e8
25. A.K. Sfakianaki, and E.R. Norwitz Mechanisms of progesterone action in inhibiting prematurity J Matern Fetal Neonatal Med 19 2006 763 772
26. T.A. Manuck, Y. Lai, P.J. Meis, and et al. Progesterone receptor polymorphisms and clinical response to 17-alphahydroxyprogesterone caproate Am J Obstet Gynecol 205 2011 135.e1 135.e9
27. A.E. Fucron, R. Romero, O. Plazyo, and et al. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has anti-inflammatory effects at the murine maternal-fetal interface Am J Obstet Gynecol 2015 Epub ahead of print
28. R. Smith, J.I. Smith, X. Shen, and et al. Patterns of plasma corticotrophin-releasing hormone, progesterone, estradiol, and estriol change and the onset of human labor J Clin Endocrinol Metab 94 2009 2066 2094
29. N.K. Ruddock, S.Q. Shi, S. Jain, and et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions Am J Obstet Gynecol 199 2008 391.e1 391.e7
30. D. Kumar, E. Springel, R.M. Moore, and et al. Progesterone inhibits in vitro fetal membrane weakening Am J Obstet Gynecol 213 2015 520.e1 520.e9
31. J.M. O'Brien, E.A. DeFranco, C.D. Adair, and et al. for the Progesterone Vaginal Gel Study Group. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double-blind, placebo-controlled trial Ultrasound Obstet Gynecol 34 2009 653 659
32. F. Facchinetti, S. Paganelli, G. Comitini, G. Dante, and A. Volpe Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate Am J Obstet Gynecol 196 2007 453.e1 453.e4
33. C. Pessel, S. Moni, N. Zork, and et al. The effect of intramuscular progesterone on the rate of cervical shortening Am J Obstet Gynecol 209 2013 269.e1 269.e7
34. C.P. Durnwald, C.D. Lynch, H. Walker, and J.D. Iams The effect of treatment with 17 alpha- hydroxyprogesterone caproate on changes in cervical length over time Am J Obstet Gynecol 201 2009 410.e1 410.e5
35. J.M. O'Brien, S.J. Ho, N. Istwan, D.L. Rhea, G.J. Stanziano, and J.R. Barton Uterine activity in women receiving 17alpha-hydroxyprogesteronecaproate for preterm birth prevention: an observational study Am J Perinatol 27 2010 157 162
36. E.B. da Fonseca, R.E. Bittar, M.H. Carvalho, and M. Zugaib Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study Am J Obstet Gynecol 188 2003 419 424
37. R. Romero, and F.Z. Stanczyk Progesterone is not the same as 17-hydroxyprogesterone caproate: implications for obstetrical practice Am J Obstet Gynecol 208 2013 421 426
38. P.J. Meis, M. Klebanoff, E. Thom, and et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate N Engl J Med 348 2003 2379 2385
39. US Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs, January 20, 2012. Available at: www.fda.gov/downloads/advisorycommittees/committeemeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm287987.pdf. Accessed: January 27, 2012.
40. L.A. McKay, T.R. Holford, and M.B. Bracken Re-analysis of the PREGNANT trial confirms that vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix Ultrasound Obstet Gynecol 43 2014 596 597
41. E.B. Fonseca, E. Celik, M. Parra, M. Singh, and K.H. Nicolaides Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix N Engl J Med 357 2007 462 469
42. J.M. O'Brien, C.D. Adair, D.F. Lewis, and et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial Ultrasound Obstet Gynecol 30 2007 687 696
43. R. Romero, K.H. Nicolaides, A. Conde-Agudelo, and et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and meta-analysis of individual patient data Am J Obstet Gynecol 206 2012 124.e1 124.e19
44. M.A. Maher, A. Abdelaziz, M. Ellaithy, and M.F. Bazeed Prevention of preterm birth: a randomized trial of vaginal compared to intramuscular progesterone Acta Obstet Gynecol Scand 92 2013 215 222
45. S.N. Caritis, R. Venkataramanan, E. Thom, and et al. Relationship between 17-alphahydroxyprogesterone caproate concentration and spontaneous preterm birth Am J Obstet Gynecol 210 2014 128.e1 128.e6
46. S.N. Caritis, S. Sharma, R. Venkataramanan, and et al. Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation Am J Obstet Gynecol 207 2012 398.e1 398.e8
47. E. Cicinelli, D. DeZiegler, C. Bulletti, M.G. Matteo, L.M. Schonauer, and P. Galantino Direct transport of progesterone from vagina to uterus Obstet Gynecol 95 2000 403 406
48. R.A. Miles, R.J. Paulson, R.A. Lobo, M.F. Press, L. Dahmoush, and M.V. Sauer Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study Fertil Steril 62 1994 485 490
49. A. Conde-Agudelo, and R. Romero Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications Am J Obstet Gynecol 2015 Epub ahead of print
50. E.A. DeFranco, J.M. O'Brien, C.D. Adair, and et al. Vaginal progesterone is associated with a decreased risk of early preterm birth and improved neonatal outcome in women with a short cervix Ultrasound Obstet Gynecol 30 2007 697 705
51. S.S. Hassan, R. Romero, D. Vidyadhari, and et al. for the PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographically short cervix: a multicenter, randomized, double-blind, placebo-controlled trial Ultrasound Obstet Gynecol 38 2011 18 31
52. W.A. Grobman, E.A. Thom, C.Y. Spong, and et al. 17 Alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm Am J Obstet Gynecol 207 2012 390.e1 390.e8
53. N. Winer, F. Bretelle, M.V. Senat, and et al. 17 Alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial Am J Obstet Gynecol 212 2015 485.e1 485.e10
54. P. Rozenberg, A. Chauveaud, P. Deruelle, and et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial Am J Obstet Gynecol 206 2012 206.e1 206.e9
55. A. Sotiriadis, S. Papatheodorou, and G. Makrydimas Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis Ultrasound Obstet Gynecol 40 2012 257 266
56. E. Schuit, S. Stock, L. Rode, and et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis BJOG 122 2015 27 37
57. A.C. Lim, E. Schuit, K. Bloemenkamp, and et al. 17Alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial Obstet Gynecol 118 2011 513 520
58. M.V. Senat, R. Porcher, N. Winer, and et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial Am J Obstet Gynecol 208 2013 194.e1 194.e8
59. J.E. Norman, F. Mackenzie, P. Owen, and et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis Lancet 373 2009 2034 2040
60. L. Rode, K. Klein, K.H. Nicolaides, and et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone Ultrasound Obstet Gynecol 38 2011 272 280
61. C.A. Combs, T. Garite, K. Maurel, A. Das, M. Porto for the Obstetrix Collaborative Research Network Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial Am J Obstet Gynecol 203 2010 248.e1 248.e9
62. S.N. Caritis, D.J. Rouse, A.M. Peaceman, and et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial Obstet Gynecol 113 2009 285 292
63. C.A. Combs, T. Garite, K. Maurel, A. Das, M. Porto Obstetrix Collaborative Research Network 17-Hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial Am J Obstet Gynecol 204 2011 221.e1 221.e8
64. D.J. Rouse, S.N. Caritis, A.M. Peaceman, and et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins N Engl J Med 357 2007 454 461
65. M.L. Brizot, W. Hernandez, A.W. Liao, and et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study Am J Obstet Gynecol 213 2015 82.e1 82.e9
66. C.A. Combs, T.J. Garite, K. Maurel, and et al. 17-Hydroxyprogesterone caproate for preterm rupture of the membranes; a multicenter, randomized, double-blind, placebo-controlled trial Am J Obstet Gynecol 213 2015 364.e1 364.e12
67. B. Martinez de Tejada, A. Karolinski, M.C. Ocampo, and et al. for the 4P trial group. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial BJOG 122 2015 80 93
68. A. Suhag, G. Saccone, and V. Berghella Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials Am J Obstet Gynecol 213 2015 479 487
69. G. Saccone, A. Suhag, and V. Berghella 17-Alphahydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials Am J Obstet Gynecol 213 2015 16 22
70. Society of Maternal-Fetal Medicine (SMFM) Chauhan SP, Blackwell SC. SMFM adopts GRADE (Grading of Recommendations Assessment, Development, and Evaluation) for clinical guidelines Am J Obstet Gynecol 209 2013 163 165
71. Food and Drug Administration. 17α-Alpha hydroxyprogesterone caproate for prevention of preterm birth: overview of FDA background document. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf Accessed: July 13, 2007.
72. J.M. O'Brien, and D.F. Lewis Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies J Reprod Med 54 2009 73 87
73. J.M. O'Brien The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment Am J Perinatol 29 2012 665 672
74. J.M. O'Brien Progestogen safety in multiple gestations: application of the Bradford Hill criteria BJOG 122 2015 610 614
75. J.M. O'Brien Mortality related to 17-OHPC exposure is an important safety outcome Am J Obstet Gynecol 209 2013 282 283
76. J. Awwad, I.M. Usta, G. Ghazeeri, and et al. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity BJOG 122 2015 71 79
77. W. El-refaie, M. Abdelhafez, and A. Badawy Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety Arch Gynecol Obstet 2015 Epub ahead of print
78. S.G. Brubaker, C. Pessel, N. Zork, C. Gyamfi-Bannerman, and C.V. Ananth Vaginal progesterone in women with twin gestations complicated by short cervix: a retrospective cohort study BJOG 122 2015 712 718
79. Z. Katz, M. Lancet, J. Skornik, J. Chemke, B.M. Mogilner, and M. Klinberg Teratogenicity of progestogens given during the first trimester of pregnancy Obstet Gynecol 65 1985 775 780
80. I. Dudas, J. Gidai, and A.E. Czeizel Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy Congenit Anom Kyoto 46 2006 194 198
81. J. Willing, and C.K. Wagner Exposure to the synthetic progestin, 17alpha-hydroxyprogesterone caproate during development impairs cognitive flexibility in adulthood Endocrinology 2015 10.1210/en.2015-1775
82. C.K. Wagner Progesterone receptors and neural development: a gap between bench and bedside? Endocrinology 149 2008 2743 2749
83. A.T. Norman, G.S. Norman, K. Anderson, and et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo Obstet Gynecol 110 2007 865 872
84. H.C. McNamara, R. Wood, J. Chalmers, and et al. STOPPIT baby follow-up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome PLoS One 10 2015 e0122341
85. J.M. O'Brien, J.J. Steichen, J.A. Phillips, and G.W. Creasy Two year infant outcomes for children exposed to supplemental progesterone gel in utero: secondary analysis of a multicenter, randomized, double-blind, placebo-controlled trial Am J Obstet Gynecol 206 suppl 2012 S223
86. E.R. Simpson, and P.C. MacDonald Endocrine physiology of the placenta Ann Rev Physiol 43 1981 163 188
87. M.A. Elovitz, and C. Mrinalini The use of progestational agents for preterm birth: lessons from a mouse model Am J Obstet Gynecol 195 2006 1004 1010
88. American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 142: Cerclage for the management of cervical insufficiency Obstet Gynecol 123 2014 372 379
89. V. Berghella, A.O. Odibo, M.S. To, O.A. Rust, and S.M. Althuisius Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data Obstet Gynecol 106 2005 181 189
90. M. Goya, L. Pratcorona, C. Merced, and et al. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomized controlled trial Lancet 379 2012 1800 1806
91. E.S. Miller, W.A. Grobman, L. Fonseca, and B.K. Robinson Indomethacin and antibiotics in examination-indicated cerclage: a randomized trial Obstet Gynecol 123 2014 1311 1316
92. J.R. Barton, L.A. Barton, N.B. Istwan, D.J. Rhea, C.N. Desch, and B.M. Sibai 17-αHydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence? Am J Obstet Gynecol 205 2011 269.e1 269.e6
93. K.D. Heyborne, A.A. Allhouse, and J.C. Carey Does 17-alphahydroxyprogesterone caproate prevent recurrent preterm birth in obese women Am J Obstet Gynecol 2015 Epub ahead of print
94. A.L. Co, H.C. Walker, E.M. Hade, and J.D. Iams Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate Am J Obstet Gynecol 213 2015 233.e1 233.e5
95. C.Y. Spong, P.J. Meis, E.A. Thom, and et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery Am J Obstet Gynecol 193 2005 1127 1131
96. J.M. Dodd, L. Jones, V. Flenady, R. Cincotta, and C.A. Crowther Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth Cochrane Database Syst Rev 7 2013 CD004947
97. L.T. Pizzi, N.S. Seligman, J.K. Baxter, E. Jutkowitz, and V. Berghella Cost and cost effectiveness of vaginal progesterone gel in reducing preterm birth: an economic analysis of the PREGNANT trial Pharmacoeconomics 32 2014 467 478
98. E.F. Werner, M.S. Hamel, K. Orzechowski, V. Berghella, and S.F. Thung Cost-effectiveness of transvaginal ultrasound cervical length screening in singletons without a prior preterm birth: an update Am J Obstet Gynecol 213 2015 554.e1 554.e6
99. Food and Drug Administration. Hydroxyprogesterone caproate. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm402614.htm. Accessed: December 11, 2014.
100. G.H. Guyatt, A.D. Oxman, G. Vist, et al. for the GRADE Working Group Rating the quality of evidence and strength of recommendations GRADE: an emerging consensus on rating the quality of evidence and strength of recommendations BMJ 336 2008 924 926